Clinical trials: sargramostim, completed
Breast Cancer
Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. It is not yet known which vaccine is most effective in treating breast cancer.
- Trial name
- NCT00640861
- Testing
- CpG oligodeoxynucleotide, HER-2/neu peptide vaccine, MUC-1 peptide vaccine
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Mayo Clinic
Breast Neoplasms, Neoplasm Metastasis
Phase I Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Plus GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor) Plus Dose Escalation of IL-3 (Interleukin-3) in Metastatic Breast Cancer
This is a phase I study to determine the maximal tolerated dose of IL-3 given alone or sequentially with GM-CSF following FLAC chemotherapy in metastatic breast cancer patients.
- Trial name
- NCT00001269
- Testing
- IL-3
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma, Alveolar Soft Part
Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
Background: Alveolar soft part sarcoma (ASPS) is a rare, highly vascular tumor accounting for less than 1% of soft tissue sarcomas. There is no effective systemic treatment for patients with metastatic ASPS.
- Trial name
- NCT01391962
- Testing
- Cediranib, Sunitinib, Prochlorperazine
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Ovarian Cancer
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
This is a single-center, randomized, single-blinded, three-arm phase Ib study of the folate binding protein vaccines E39 and J65.
- Trial name
- J65 (NCT02019524)
- Testing
- E39 peptide vaccine, E39 vaccine then J65 vaccine, J65 vaccine then E39 vaccine
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- COL George Peoples, MD, FACS
Recurrent Prostate Cancer, Stage I Prostate Cancer
The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer
This randomized pilot phase I trial studies how well sargramostim after cryotherapy works in treating patients with prostate cancer.
- Conditions
- Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
- Trial name
- NCT02250014
- Testing
- cryotherapy, sargramostim
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Colorado, Denver
Pancreatic Cancer
Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00425360
- Testing
- sargramostim, telomerase peptide vaccine GV1001, capecitabine
- Where
- 45 sites in United Kingdom
- Volunteers
- 1,110 people
- Sponsor
- Royal Liverpool University Hospital
Neuroblastoma
Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma
The purpose of this study is to be able to supply an experimental combination of drugs called 3F8 and GM-CSF (also called sargramostim) to patients with high-risk neuroblastoma who may benefit from treatment.
- Trial name
- NCT02100930
- Testing
- Anti-GD2 3F8 Monoclonal Antibody, GM-CSF (granulocyte-macrophage colony-stimulating factor), oral isotretinoin
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Cancer
Microsphere-Delivered Cytokines in Increasing Tumor Response in Lymphocytes From Patients With Head and Neck Cancer
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about how interleukin-2, interleukin-12, and GM-CSF delivered in microspheres increase the body's ability to kill…
- Trial name
- NCT00899821
- Testing
- aldesleukin, recombinant interleukin-12, sargramostim
- Sponsor
- NYU Langone Health
Breast Cancer, Cervical Cancer
Vaccine Therapy and Biological Therapy in Treating Patients With Advanced Cancer
RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells.
- Conditions
- Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer
- Trial name
- NCT00019084
- Testing
- aldesleukin, mutant p53 peptide pulsed dendritic cell vaccine, ras peptide cancer vaccine
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Neuroblastoma
MIBG With Dinutuximab +/- Vorinostat
131I-Metaiodobenzylguanidine (131I-MIBG) is one of the most effective therapies utilized for neuroblastoma patients with refractory or relapsed disease.
- Trial name
- NCT03332667
- Testing
- 131I-MIBG, Dinutuximab, Vorinostat
- Where
- 12 sites in United States
- Volunteers
- 45 people
- Sponsor
- New Approaches to Neuroblastoma Therapy Consortium
Melanoma (Skin)
Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00004184
- Testing
- monoclonal antibody 4B5 anti-idiotype vaccine, sargramostim, alum adjuvant
- Volunteers
- 50 people
- Sponsor
- University of Alabama at Birmingham
Infertility
Efficacy Study of Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) for Use in Human IVF
This study is to assess whether addition of 2 ng/ml GM-CSF into a specific culture medium will increase the chance of a pregnancy after in vitro fertilisation.
- Trial name
- GM-CSF (NCT00565747)
- Testing
- Test culture, Control culture
- Where
- 14 sites in Denmark, Sweden
- Volunteers
- 1,332 people
- Sponsor
- Origio A/S
Chronic Lymphocytic Leukemia
FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia
The goal of this clinical research study is to learn if using a combination of fludarabine, cyclophosphamide, and rituximab, with sargramostim (GM-CSF) can help to control previously untreated chronic lymphocytic leukemia (CLL).
- Trial name
- NCT00381004
- Testing
- Cyclophosphamide, Fludarabine, Sargramostim
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Renal Cancer
Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
The main purpose of this study is to test the safety of the dendritic cell/tumor fusion study vaccine in combination with a laboratory-made agent called Granulocyte Macrophage Colony Stimulating Factor (GM-CSF).
- Trial name
- NCT00458536
- Testing
- Dendritic Cell Tumor Fusion Vaccine, Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Beth Israel Deaconess Medical Center
Leukemia
A Randomized Phase III Study of Intensive Consolidation With High Dose Cytosine Arabinoside in Acute Myelogenous Leukemia (AML-8B)
RATIONALE: Patient abstract not available PURPOSE: Patient abstract not available
- Trial name
- NCT01324063
- Testing
- sargramostim, amsacrine, cytarabine
- Volunteers
- 160 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Melanoma
Evaluation of the Effects of Local Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Adjuvant Administration on Dendritic Cells in Skin of Melanoma Patients and in Sentinel Lymph Nodes: MEL38
Goal: To characterize the cellular events that occur in vivo after vaccination with an emulsion of GMCSF-in-adjuvant. Design: Open-label, single dose study in two stages.
- Trial name
- MEL38 (NCT00912574)
- Testing
- GM-CSF-in-adjuvant, Montanide ISA-51, GM-CSF and Montanide ISA-51
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Virginia
Lymphoma
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Trial name
- NCT00002461
- Testing
- filgrastim, sargramostim, carmustine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Montefiore Medical Center
Fallopian Tube Cancer, Ovarian Cancer
Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
This was a Phase 1, non-randomized, open-label, multicenter study of the ALVAC(2)-NY-ESO-1(M)/TRICOM vaccine administered with the granulocyte macrophage-colony stimulating factor (GM-CSF) sargramostim in patients with NY-ESO-1…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00803569
- Testing
- ALVAC(2)-NY-ESO-1(M)/TRICOM vaccine, Sargramostim
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Ludwig Institute for Cancer Research
Metastatic Prostate Cancer
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
This is a randomized, open-label study designed to assess the effects of sipuleucel-T when administered concurrently or sequentially with enzalutamide.
- Trial name
- NCT01981122
- Testing
- sipuleucel-T, enzalutamide
- Where
- 19 sites in United States
- Volunteers
- 52 people
- Sponsor
- Dendreon
Melanoma (Skin)
Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Vaccines made from melanoma cells may make the body build an immune response to and kill tumor cells. Colony-stimulating factors such as GM-CSF may increase the number of immune cells found in the bone marrow or…
- Trial name
- NCT00003222
- Testing
- aldesleukin, gp100 antigen, incomplete Freund's adjuvant
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Virginia